Cancer

News

Merck aims for first line kidney cancer use for Keytruda com...

Merck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing that it improved survival in combination with Pfizer’s Inlyta compared

News

Amgen invests £50m in UK genetics firm Oxford Nanopore

Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology.

News

Novartis to buy cancer drug firm Endocyte for $2.1bn

Novartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash.

News

Pfizer's Talzenna PARP breast cancer drug approved in US

The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation.

News

Roche beats revenue forecasts as sales of old drugs take off...

Roche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in China and the success of newer drugs mitigated the impact of patent expiries.

News

Roche and SQZ expand cell therapy deal to more than $1.3bn

US biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting cells, which may be able to target solid tumours and which are

Merck aims for first line kidney cancer use for Keytruda com...

Amgen invests £50m in UK genetics firm Oxford Nanopore

Novartis to buy cancer drug firm Endocyte for $2.1bn

Pfizer's Talzenna PARP breast cancer drug approved in US

Roche beats revenue forecasts as sales of old drugs take off...

Roche and SQZ expand cell therapy deal to more than $1.3bn

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Cancer

Editor's Picks